ArticleCancer gene therapy2013
Transfection of Kasumi-1 cells with a new type of polymer carriers loaded with miR-155 and antago-miR-155.
Article in Cancer gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 20 citations in OpenAlex.
- Perspectives on the Use of Small Noncoding RNAs as a Therapy for Severe Virus-Induced Disease Manifestations and Late Complications.BioNanoScience · 2022Review
- Non-coding RNAs and potential therapeutic targeting in cancer.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- The full recovery of mice (Mus Musculus C57BL/6 strain) from virus-induced sarcoma after treatment with a complex of DDMC delivery system and sncRNAs.Non-coding RNA research · 2019Article
- miR-155 drives oncogenesis by promoting and cooperating with mutations in the c-Kit oncogene.Oncogene · 2019Article
- Reprogramming of CaCo2 colorectal cancer cells after using the complex of poly-(N-vinylpyrrolidone) with small non-coding RNAs.Toxicology reports · 2019Article
- Long noncoding RNA CNALPTC1 promotes cell proliferation and migration of papillary thyroid cancer via sponging miR-30 family.American journal of cancer research · 2018Article
- Small non-coding RNAs as regulators of structural evolution and carcinogenesis.Non-coding RNA research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have demonstrated functional roles for microRNAs (miRNAs) in various aspects of normal and malignant hematopoiesis, including lineage commitment, differentiation, apoptosis and maturation. In vivo delivery of naked DNA, oligonucleotides and miRNAs is complicated by their low stability, rapid degradation and inefficient delivery into target cells. In our experiments, we used a new type of polymer carriers to monitor the effects of miR-155 and antago-miR-155 on the morphology and genetics of Kasumi-1 cells. We obtained platelet-like cells from leukemic cells, and detected the expression of platelet marker genes after transfection with antago-miR-155. Our findings suggest that administration of miR mimics or antago-miRs as therapeutic agents is a desirable goal for future treatment of hematologic malignancies and that polymer-based carriers for the delivery of miR mimics or antago-miRs may provide a solution to the challenges of standard miR delivery approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.